Skip to content
- Interferon-gamma release assay positivity in populations at high risk of TB infection. Dagnew AF, Han LL, Cinar A, Gaikwad D, Garcia-Basteiro AL, Gler MT, Hadinegoro SR, Hanekom WA, Lama JR, Muyoyeta M, Musala S, Nduba V, Rolla VC, Roy T, Sutherland JS. Viegas S, Wajja A, Walker TM, Noble R, Schlehuber L, Sunshine, Schmidt AC. 2026 Apr; 3(4):232-240. doi:10.5588/ijtldopen.25.0684
- The immunometabolic topography of cellular organization and bacterial control in tuberculosis granulomas. McCaffrey EF, Delmastro AC, Fitzhugh I, Ranek JS, Douglas S, Peters JM, Fullaway CC, Bosse M, Liu CC, Gillen C, Greenwald NF, Anzick S, Martens C, Winfree S, Bai Y, Sowers C, Goldston M, Kong A, Boonrat P, Bigbee CL, Venugopalan R, Maiello P, Klein E, Rodgers MA, Scanga CA, Lin PL, Bendall SC, Kirschner DE, Fortune SM, Bryson BD, Butler JR, Mattila JT, Flynn JL, Angelo M. Nat Immunol. 2026 Apr;27(4):867-880. doi: 10.1038/s41590-026-02431-8. Epub 2026 Feb 23.
- Expression of CD103 facilitates localization and activation of CD4+T cells within Mycobacterium tuberculosis lung-lesions. Lindenstrøm T, Panagiotopoulou N, Cohen SB, Rodriguez PT, Woodworth JS, Morikawa M, Halima M, Maymann CM, Hu T, Stull SM, Woetmann A, Andersen PL, Urdahl KB, Gern BH, Mortensen R. Mucosal Immunol. 2026 Apr;19(2):1937-1953. doi: 10.1016/j.mucimm.2026.02.001. Epub 2026 Feb 3.
- Immunotherapy targeting drug-tolerant Mycobacterium tuberculosis persisters accelerates tuberculosis cure in preclinical models. Karanika S, Wang T, Yilma A, Ruelas Castillo J, Gordy JT, Bailey H, Quijada D, Fessler K, Tasneen R, Rouse Salcido EM, Shamma F, Harris HT, Chen F, Bates RE, Ton H, Meza J, Li Y, Taylor AD, Zheng JJ, Zhang J, Karantanos T, Maxwell AR, Nuermberger E, Peske JD, Markham RB, Karakousis PC. J Clin Invest. 2026 Feb 3;136(7):e196648. eCollection 2026 Apr 1. doi: 10.1172/JCI196648.
- Attitudes towards new tuberculosis vaccines among adults, adolescents and their caregivers in southern Mozambique, 2024. Lima A, Campos I, Kim D, Shiiba M, Cranmer LM, Acácio S, García-Basteiro AL, Vasudevan L, Nelson K. medRxiv [Preprint]. 2026 Apr 1:2026.03.30.26349798. doi: 10.64898/2026.03.30.26349798.
- Molecular mechanisms of immune evasion by host protein glycosylation of a bacterial immunogen used in nucleic acid vaccines. Cinar MS, Adams TM, Nawaz Z, Demir ES, Demirturk ME, Keelaghan AP, Nazaar SM, Roberts BR, Ozdilek A, Avci FY. J Biol Chem. 2026 Apr 2:111423. doi: 10.1016/j.jbc.2026.111423. Epub ahead of print.
- Mycobacterium tuberculosis bacteriology and immunity necessitate a multi-pronged immune strategy for vaccination. Poolman JT. NPJ Vaccines. 2026 Apr 4. doi: 10.1038/s41541-026-01387-y. Epub ahead of print.
- Leveraging a synthetic biology approach to enhance BCG-mediated expansion of Vγ9Vδ2 T cells. Qabar CM, Roberts AW, Waldburger LM, Baidoo EEK, Turumtay EA, Keasling JD, Portnoy DA, Cox JS. PLoS One. 2026 Apr 6;21(4):e0343925. doi: 10.1371/journal.pone.0343925.
- Efficacy and safety of VPM1002 and Immuvac in preventing tuberculosis: phase 3 randomised clinical trial (PreVenTB trial). Singh M, Joshi S, Vohra V, Sarin R, Kamble SV, Velayutham B, Mohan A, Singh UB, Kumar R, Pati S, Pattnaik M, Mohapatra PR, Shankar U, Narasimhaiah S, Yadav G, Hissar S, Rodrigues R, Kadam AV, Paramasivam PK, Kambhampati S, Newtonraj A, Palaniappan NA, Reddy SD, Bhuniya S, Mishra BK, Shete A, Hanna LE, Mitra DK, Panda S, Guleria R, Tripathy S, Roy N, D’Souza G, Tripathy SK, Katoch K, Pandey RM, Sah S, Kashyap M, Telasey V, Bakshi M, Wadhwa N, Khan AM, Gangakhedkar RR, Rani R. 2026 Apr 9;393:e085716. doi: 10.1136/bmj-2025-085716. Erratum in: BMJ. 2026 Apr 21;393:s751. doi: 10.1136/bmj.s751.
- An ESAT-6-convergent prime-boost vaccination combining recombinant BCG expressing Mycobacterium marinum ESX-1 and ESAT-6/GLA-SE improves TB protection. Kwon KW, Kim H, Kim H, Brosch R, Shin SJ. NPJ Vaccines. 2026 Apr 10. doi: 10.1038/s41541-026-01439-3. Epub ahead of print.
- Multimodal profiling reveals Mycobacterium tuberculosisrestricts lung mitochondrial immunometabolism to promote pathogenesis. Dkhar HK, Bajpai P, Enriquez AB, Hopkins LB, Dawa S, Sia JK, Paul A, Madan-Lala R, Keenum MC, Sharma A, Pelletier AN, Goh SL, Riddick TLB, Whitworth TJ, Prater KE, Guerrero-Ferreira RC, Collins J, Rengarajan J. bioRxiv [Preprint]. 2026 Apr 10:2026.04.07.717012. doi: 10.64898/2026.04.07.717012.
- Application of luminescence-producing Mycobacterium tuberculosis strains for evaluating anti-tuberculosis drug and vaccine efficacy in vitro and in vivo. Kim SM, Shin E, Yun JS, Jeon J, Park S, Jeong HS, Jung YW, Kim D. BMC Infect Dis. 2026 Apr 11. doi: 10.1186/s12879-026-13140-w. Epub ahead of print.
- Immunodominant Tuberculosis Antigens Recognized by Human CD4+and CD8+ T Cells. Lewinsohn DA, Lindestam Arlehamn CS, Sette A, Lewinsohn DM. Cold Spring Harb Perspect Med. 2026 Apr 17:a041816. doi: 10.1101/cshperspect.a041816. Epub ahead of print.
- Host Biomarkers in Tuberculosis. Shaw JA, Walzl G. Cold Spring Harb Perspect Med. 2026 Apr 17:a041833. doi: 10.1101/cshperspect.a041833. Epub ahead of print.
- Anticipating tuberculosis vaccine acceptability in Kenya and South Africa: a narrative review of behavioral and social drivers and strategies to optimize acceptability. Giovanatti A, Shapiro AE. Vaccine. 2026 Apr 19;79:128457. doi: 10.1016/j.vaccine.2026.128457. Epub 2026 Mar 13.
- Hypoxia restricts the generation of BCG-responsive polycytotoxic T cells. de Dieu Harelimana J, Bürger M, Zumwinkel M, Mohnani J, Weper M, Romahn V, Zähnle M, Grieshober M, Stenger S. Vaccine. 2026 Apr 19;79:128456. doi: 10.1016/j.vaccine.2026.128456. Epub 2026 Mar 11.
- Reinfection as a central constraint on tuberculosis vaccine development. Cardona PJ. Front Immunol. 2026 Apr 21;17:1807344. doi: 10.3389/fimmu.2026.1807344.
- Acceptability of a proposed new tuberculosis vaccine among people deprived of liberty in Brazil. Bampi JVB, Arcanjo GGA, Santos KM, Ventura MS, Lemos EF, Clark RA, Thomas KA, White RG, Croda J. Vaccine. 2026 Apr 19;79:128492. doi: 10.1016/j.vaccine.2026.128492. Epub 2026 Mar 18.
- Enhancing tuberculosis vaccine efficacy with a heterologous mRNA-ChAdOx1 prime-pull strategy targeting lung-resident memory T cells. Korompis M, De Voss CJ, Li S, Ateere A, McShane H, Stylianou E. Front Immunol. 2026 Apr 20;17:1807190. doi: 10.3389/fimmu.2026.1807190.
- Context-specific roles for IL-17 in tuberculosis. Maseeme M, Tezera LB, Noursadeghi M, Leslie A, Pollara G. PLoS Pathog. 2026 Apr 21;22(4):e1014054. doi: 10.1371/journal.ppat.1014054.
- Construction and characterization of novel Mycobacterium tuberculosis-derived triple and quadruple knockout vaccines against tuberculosis. Garnica O, Veerapandian R, Das K, Mishra A, Rawat V, Carmona A, Chauhan V, Kumar R, Chacon J, Khan A, Ramos EI, Gadad SS, Jagannath C, Dhandayuthapani S. Infect Immun. 2026 Apr 21:e0050025. doi: 10.1128/iai.00500-25. Epub ahead of print.
- Understanding adjuvant supply chains for new TB and malaria vaccines. Gotham D, Frick M, Harrington M. 2026 Apr 22;82:128609. doi: 10.1016/j.vaccine.2026.128609. Epub ahead of print. PMID: 42025104.
- Complement in tuberculosis infection and disease, a battle of two ancients. Dijkman K, Joosten SA, Trouw LA. Immunobiology. 2026 Apr 25;231(3):153183. doi: 10.1016/j.imbio.2026.153183. Epub ahead of print.
- Single-cell profiling reveals that dynamic lung immune responses distinguish protection from susceptibility to tuberculosis. Duffy FJ, Neal ML, Plumlee CR, Cohen SB, Gern BH, Diercks AH, Gerner MY, Urdahl KB, Aitchison JD. PLoS Pathog. 2026 Apr 27;22(4):e1013635. doi: 10.1371/journal.ppat.1013635.
- Extrapulmonary tuberculosis is understudied in preventive vaccine trials. Singh M, Pati S. BMJ. 2026 Apr 30;393:s835. doi: 10.1136/bmj.s835.
